Inhibition of Mutated, Activated BRAF in Metastatic MelanomaKeith T. Flaherty, Paul B. Chapman, Igor Puzanov et al.|New England Journal of Medicine|2010Cited by 3.5k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Peter Hirth et al.|Nature|2010Cited by 1.8k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Matteo S. Carlino et al.|The Lancet|2024Cited by 729
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged SkinF. Stephen Hodi, David E. Fisher, Christopher L. Corless et al.|Journal of Clinical Oncology|2013Cited by 594
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Ngocdiep T. Le et al.|The Lancet Oncology|2012Cited by 541